{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011501","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.109934+00:00","generated_at":"2026-06-25T02:50:10.779642+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Beam Therapeutics shareholders elect three Class II directors, ratify auditor, approve say-on-pay","bullets":["All three director nominees (Fishman, Ho, Walsh) elected with ~39.5M votes each.","Deloitte & Touche ratified as auditor for FY2022 with 51.8M for, 3.1M against.","Advisory vote on executive compensation approved with 36.9M for, 5.7M against.","Shareholders selected every year as the frequency of say-on-pay votes; board adopts annual policy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011501","json":"https://secwatch.observer/filing/0000950170-22-011501.json","markdown":"https://secwatch.observer/filing/0000950170-22-011501.md","text":"https://secwatch.observer/filing/0000950170-22-011501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022011501/0000950170-22-011501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022011501/beam-20220608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:50:10.779642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}